Co-Authors
This is a "connection" page, showing publications co-authored by Simon Cauchemez and Juliette Paireau.
Connection Strength
1.621
-
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. Euro Surveill. 2021 07; 26(26).
Score: 0.238
-
Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health. 2021 06; 6(6):e408-e415.
Score: 0.235
-
Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis. Lancet Reg Health Eur. 2021 Jun; 5:100087.
Score: 0.234
-
Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French Guiana. Nat Commun. 2021 03 12; 12(1):1634.
Score: 0.233
-
Lockdown impact on COVID-19 epidemics in regions across metropolitan France. Lancet. 2020 10 10; 396(10257):1068-1069.
Score: 0.226
-
Estimating the burden of SARS-CoV-2 in France. Science. 2020 07 10; 369(6500):208-211.
Score: 0.220
-
Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic wave. Sci Rep. 2021 06 17; 11(1):12756.
Score: 0.059
-
Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. Lancet Reg Health Eur. 2021 Aug; 7:100148.
Score: 0.059
-
Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. Infect Dis Now. 2021 Jun; 51(4):380-382.
Score: 0.058
-
Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021 02; 590(7844):140-145.
Score: 0.057